Physician profile

Husam H Balkhy

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Chicago, IL

NPI 1790750891

$129,301.88

in general payments reported to CMS, 2019-2025

21 companies · $60K in 2025

The $60K reported for 2025 was more than what 98% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).

See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$40,961.72
Education$29,300.00
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$17,137.50
Food and Beverage$7,952.62
Travel and Lodging$3,863.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $47,041.80 2019-2025 Da Vinci Surgical System, Da Vinci Sp
Edwards Lifesciences Corporation $35,237.17 2019-2025 Mitris Resilia Mitral Valve, Thruport Systems Intraclude Intra-Aortic Occlusion Device, Inspiris Resilia Aortic Valve
Medtronic, INC. $15,645.42 2021-2025 Simulus, Avalus, Endurant Iis
Corcym INC $10,173.46 2022-2025 Perceval, Carbomedics Supra-Annular (Top Hat), Mi Detach - Aortic Cross Clamp - Delivery System Kit
Enablecv INC. $8,931.60 2024-2025 Thruport Systems Intraclude Intra-Aortic Occlusion Device
Lsi Solutions INC $3,337.51 2019-2025 Cor-Knot, Minirumel, Sew-Easy
Atricure, INC. $3,037.12 2019-2024
Ethicon INC. $2,520.21 2025 Prolene, Vistaseal
Medical Device Business Services, INC. $620.00 2025 Prolene, Vistaseal
Medistim USA, INC. $567.39 2019-2023 Miraq
Medela LLC $436.02 2025
Elutia, INC. $363.26 2019
Maquet Cardiovascular L.L.C. $274.48 2023-2025 Acrobat-I Stabilizer, Acrobat-I Stabilizer
Livanova USA, INC. $238.42 2019-2020
Surgical Specialties Corporation (US), INC. (Dba Corza Medical) $179.78 2025
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Abbott Laboratories $157.71 2020-2023 Thoratec Heartmate 3 Lvas Implant Kit
Medtronic Vascular, INC. $141.55 2019
Conmed Corporation $136.49 2022
Getinge USA Sales, LLC $117.65 2019
Aesculap Ag $90.91 2019
Arthrex, INC. $53.93 2023 Shoulder Suture Fiberwire Cerclage

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$13,018.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Husam H Balkhy

$129,301.88

in general payments reported 2019-2025

Years
2019-2025
Top company
Edwards Lifesciences Corporation
Context
The $60K reported for 2025 was more than what 98% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).

https://glasscript.com/doctor/80522/husam-h-balkhy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.